First Time Loading...

Roche Holding AG
SIX:ROG

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
SIX:ROG
Watchlist
Price: 245 CHF -1.05%
Updated: Jun 17, 2024
Have any thoughts about
Roche Holding AG?
Write Note

Intrinsic Value

Roche Holding AG operates as a research healthcare company. [ Read More ]

The intrinsic value of one ROG stock under the Base Case scenario is 343.31 CHF. Compared to the current market price of 245 CHF, Roche Holding AG is Undervalued by 29%.

Key Points:
ROG Intrinsic Value
Base Case
343.31 CHF
Undervaluation 29%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Roche Holding AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ROG stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Roche Holding AG

Current Assets 33.4B
Cash & Short-Term Investments 10.5B
Receivables 11.4B
Other Current Assets 11.6B
Non-Current Assets 57B
PP&E 22.9B
Intangibles 24.2B
Other Non-Current Assets 9.9B
Current Liabilities 24.8B
Accounts Payable 4.3B
Short-Term Debt 1.4B
Other Current Liabilities 19.1B
Non-Current Liabilities 36.3B
Long-Term Debt 24.8B
Other Non-Current Liabilities 11.5B
Efficiency

Earnings Waterfall
Roche Holding AG

Revenue
58.7B CHF
Cost of Revenue
-15.6B CHF
Gross Profit
43.1B CHF
Operating Expenses
-24.6B CHF
Operating Income
18.5B CHF
Other Expenses
-7B CHF
Net Income
11.5B CHF

Free Cash Flow Analysis
Roche Holding AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ROG Profitability Score
Profitability Due Diligence

Roche Holding AG's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Positive Free Cash Flow
Exceptional ROE
71/100
Profitability
Score

Roche Holding AG's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

ROG Solvency Score
Solvency Due Diligence

Roche Holding AG's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Long-Term Solvency
Short-Term Solvency
68/100
Solvency
Score

Roche Holding AG's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ROG Price Targets Summary
Roche Holding AG

Wall Street analysts forecast ROG stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ROG is 276.85 CHF with a low forecast of 217.15 CHF and a high forecast of 449.4 CHF.

Lowest
Price Target
217.15 CHF
11% Downside
Average
Price Target
276.85 CHF
13% Upside
Highest
Price Target
449.4 CHF
83% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

ROG Price
Roche Holding AG

1M 1M
+3%
6M 6M
0%
1Y 1Y
-11%
3Y 3Y
-25%
5Y 5Y
+1%
10Y 10Y
+23%
Annual Price Range
245
52w Low
214.1
52w High
276.8
Price Metrics
Average Annual Return 5.4%
Standard Deviation of Annual Returns 20%
Max Drawdown -45%
Shares Statistics
Market Capitalization 195.1B CHF
Shares Outstanding 804 000 000
Percentage of Shares Shorted
N/A

ROG Return Decomposition
Main factors of price return

What is price return decomposition?

ROG News

Other Videos

Last Important Events
Roche Holding AG

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Roche Holding AG

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Roche Holding AG Logo
Roche Holding AG

Country

Switzerland

Industry

Pharmaceuticals

Market Cap

195.1B CHF

Dividend Yield

3.92%

Description

Roche Holding AG operates as a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 100,920 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Contact

BASEL-STADT
Basel
Grenzacherstr. 124

IPO

2001-05-04

Employees

100 920

Officers

Executive Chairman
Dr. Severin Schwan Ph.D.
Chief Executive Officer
Dr. Thomas Schinecker
Chief Financial & Information Officer
Dr. Alan Hippe
Head of Investor Relations
Dr. Bruno Eschli
General Counsel
Ms. Claudia Bockstiegel
Chief Compliance Officer
Ms. Pascale Schmidt
Show More
Head of Group Communications
Ms. Barbara Schadler
Chief People Officer
Ms. Cristina A. Wilbur
Head of Group Media Relations
Dr. Nicolas Dunant
Head of Group Business Development and M&A
Mr. Boris L. Zaitra
Show Less

See Also

Discover More
What is the Intrinsic Value of one ROG stock?

The intrinsic value of one ROG stock under the Base Case scenario is 343.31 CHF.

Is ROG stock undervalued or overvalued?

Compared to the current market price of 245 CHF, Roche Holding AG is Undervalued by 29%.